Glanbia Targets Higher Adjusted Earnings to Reach Growth Ambitions

Dow Jones

Nov 19, 2025

By Nina Kienle

Glanbia said it targets higher adjusted earnings per share in the midterm as it sharpens its focus on growth ambitions.

The Irish nutrition group on Wednesday said it targets adjusted earnings per share growth in the range of 7% to 11% on a constant currency basis between 2026 and 2028.

It also targets return on capital employed in the range of 10% to 13%, with a progressive dividend maintained, it added.

In the performance nutrition segment the company aims for annual organic revenue growth of 5% to 7%. It targets a 250 basis point progression in its total three-year earnings before interest, taxes, depreciation, and amortization margin from its 2025 reported base.

In health and nutrition, Glanbia targets annual organic revenue growth of between 4% an 6%, as well as an Ebitda margin range of 17% to 19%.

In dairy nutrition, an annual Ebitda range of around $150 million to $160 million is targeted.

"We are well-positioned to deliver on our ambition to drive growth and shareholder returns," Chief Executive Hugh McGuire said.

Write to Nina Kienle at nina.kienle@wsj.com

(END) Dow Jones Newswires

November 19, 2025 03:11 ET (08:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584916813"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584916813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584916813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 16:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584916813","market":"fut","top_or_hot":-1,"title":"Glanbia Targets Higher Adjusted Earnings to Reach Growth Ambitions","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nina Kienle \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Glanbia said it targets higher adjusted earnings per share in the midterm as it sharpens its focus on growth ambitions. \n</p>\n<p>\n  The Irish nutrition group on Wednesday said it targets adjusted earnings per share growth in the range of 7% to 11% on a constant currency basis between 2026 and 2028. \n</p>\n<p>\n  It also targets return on capital employed in the range of 10% to 13%, with a progressive dividend maintained, it added. \n</p>\n<p>\n  In the performance nutrition segment the company aims for annual organic revenue growth of 5% to 7%. It targets a 250 basis point progression in its total three-year earnings before interest, taxes, depreciation, and amortization margin from its 2025 reported base. \n</p>\n<p>\n  In health and nutrition, Glanbia targets annual organic revenue growth of between 4% an 6%, as well as an Ebitda margin range of 17% to 19%. \n</p>\n<p>\n  In dairy nutrition, an annual Ebitda range of around $150 million to $160 million is targeted. \n</p>\n<p>\n  \"We are well-positioned to deliver on our ambition to drive growth and shareholder returns,\" Chief Executive Hugh McGuire said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nina Kienle at nina.kienle@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 19, 2025 03:11 ET (08:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glanbia Targets Higher Adjusted Earnings to Reach Growth Ambitions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlanbia Targets Higher Adjusted Earnings to Reach Growth Ambitions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-19 16:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nina Kienle \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Glanbia said it targets higher adjusted earnings per share in the midterm as it sharpens its focus on growth ambitions. \n</p>\n<p>\n  The Irish nutrition group on Wednesday said it targets adjusted earnings per share growth in the range of 7% to 11% on a constant currency basis between 2026 and 2028. \n</p>\n<p>\n  It also targets return on capital employed in the range of 10% to 13%, with a progressive dividend maintained, it added. \n</p>\n<p>\n  In the performance nutrition segment the company aims for annual organic revenue growth of 5% to 7%. It targets a 250 basis point progression in its total three-year earnings before interest, taxes, depreciation, and amortization margin from its 2025 reported base. \n</p>\n<p>\n  In health and nutrition, Glanbia targets annual organic revenue growth of between 4% an 6%, as well as an Ebitda margin range of 17% to 19%. \n</p>\n<p>\n  In dairy nutrition, an annual Ebitda range of around $150 million to $160 million is targeted. \n</p>\n<p>\n  \"We are well-positioned to deliver on our ambition to drive growth and shareholder returns,\" Chief Executive Hugh McGuire said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nina Kienle at nina.kienle@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 19, 2025 03:11 ET (08:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLAPY","symbol_name":"Glanbia Plc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2584916813","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584916813","pubTimestamp":1763539860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Glanbia said it targets higher adjusted earnings per share in the midterm as it sharpens its focus on growth ambitions.The Irish nutrition group on Wednesday said it targets adjusted earnings per share growth in the range of 7% to 11% on a constant currency basis between 2026 and 2028.It also targets return on capital employed in the range of 10% to 13%, with a progressive dividend maintained, it added.In the performance nutrition segment the company aims for annual organic revenue growth of 5% to 7%. It targets a 250 basis point progression in its total three-year earnings before interest, taxes, depreciation, and amortization margin from its 2025 reported base.In health and nutrition, Glanbia targets annual organic revenue growth of between 4% an 6%, as well as an Ebitda margin range of 17% to 19%.In dairy nutrition, an annual Ebitda range of around $150 million to $160 million is targeted.\"We are well-positioned to deliver on our ambition to drive growth and shareholder returns,\" Ch","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLAPY":"Glanbia Plc","BK4212":"包装食品与肉类"},"translate_title":"Glanbia的目标是提高调整后收益以实现增长雄心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLAPY":0.9},"content_text":"By Nina Kienle \n\n\n \n\n\n  Glanbia said it targets higher adjusted earnings per share in the midterm as it sharpens its focus on growth ambitions. \n\n\n  The Irish nutrition group on Wednesday said it targets adjusted earnings per share growth in the range of 7% to 11% on a constant currency basis between 2026 and 2028. \n\n\n  It also targets return on capital employed in the range of 10% to 13%, with a progressive dividend maintained, it added. \n\n\n  In the performance nutrition segment the company aims for annual organic revenue growth of 5% to 7%. It targets a 250 basis point progression in its total three-year earnings before interest, taxes, depreciation, and amortization margin from its 2025 reported base. \n\n\n  In health and nutrition, Glanbia targets annual organic revenue growth of between 4% an 6%, as well as an Ebitda margin range of 17% to 19%. \n\n\n  In dairy nutrition, an annual Ebitda range of around $150 million to $160 million is targeted. \n\n\n  \"We are well-positioned to deliver on our ambition to drive growth and shareholder returns,\" Chief Executive Hugh McGuire said. \n\n\n \n\n\n  Write to Nina Kienle at nina.kienle@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 03:11 ET (08:11 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}